Home » Posts tagged with » pharma acquisition news
Alexion to acquire Achillion to strengthen rare diseases portfolio

Alexion to acquire Achillion to strengthen rare diseases portfolio

Alexion acquisition of Achillion : Alexion Pharmaceuticals has agreed to acquire rival US pharma company Achillion Pharmaceuticals for about $930 million in an all-cash deal as per the latest pharma acquisition news. Achillion is a clinical-stage biopharma company, which is engaged in developing oral small molecule Factor D inhibitors for the treatment of people with […]

Sobi to acquire US pharma company Dova Pharmaceuticals in $915m deal

Sobi acquisition of Dova Pharmaceuticals : Swedish Orphan Biovitrum (Sobi) has signed a deal worth up to $915 million to acquire Dova Pharmaceuticals, a US pharma company, in a move to become a major player in hematology and orphan diseases and also for expanding its footprint in the US. Shareholders of Dova Pharmaceuticals will be […]

Continue reading …
Currax Pharmaceuticals acquires Nalpropion Pharmaceuticals

Currax Pharmaceuticals, a specialty biopharma company having branded and generic drug businesses, has acquired Nalpropion Pharmaceuticals for an undisclosed price, as per the latest pharma acquisition news. Through the acquisition, Currax gains the global rights to CONTRAVE (naltrexone HCl and bupropion HCl extended release), a prescribed weight-loss drug in the US, which has patent protection till […]

Continue reading …
Lundbeck to acquire Alder BioPharmaceuticals to extend migraine portfolio

Lundbeck acquisition of Alder BioPharmaceuticals : Danish pharma company H. Lundbeck has entered into a definitive agreement to acquire Alder BioPharmaceuticals, a US clinical-stage pharma development company, in a transaction valued at up to $1.95 billion in cash. Alder BioPharmaceuticals is engaged in discovering, development and commercialization of novel therapeutic antibodies for the preventive treatment […]

Continue reading …
Mindmed acquires 18-MC opioid addiction drug candidate from Savant HWP

Mindmed acquisition of 18-MC : Canada-based Mind Medicine (Mindmed) has acquired opioid addiction drug candidate 18-MC from Savant HWP for an undisclosed price, as per the latest pharma acquisition news. 18-MC, which is derived from ibogaine – a natural psychedelic substance, is being developed for addressing the opioid crisis and other types of addiction. The […]

Continue reading …
Castle Creek to acquire cell and gene therapy company Fibrocell

Castle Creek acquisition of Fibrocell : Castle Creek Pharmaceutical Holdings (CCP Holdings) has agreed to acquire Fibrocell Science, a cell and gene therapy company engaged in developing autologous cell-based therapies for skin and connective tissue disorders. Financial terms of the deal were not disclosed, as per the latest pharma industry news. CCP Holdings is a […]

Continue reading …
Aytu BioScience to acquire Innovus Pharmaceuticals

Aytu acquisition of Innovus : Colorado-based specialty pharma company Aytu BioScience has agreed to acquire Innovus Pharmaceuticals in a deal worth up to $24 million, as per the latest pharma acquisition news. Headquartered in California, Innovus Pharmaceuticals is an over the counter (OTC) consumer goods and specialty pharmaceutical company. On the other hand, Aytu BioScience […]

Continue reading …
Mallinckrodt to sell Canadian CDMO BioVectra to H.I.G. Capital for $250m

Mallinckrodt sale of BioVectra to H.I.G. Capital : Irish biopharma company Mallinckrodt has agreed to divest its wholly-owned subsidiary BioVectra, a Canadian CDMO (contract development and manufacturing organization) to an affiliate of H.I.G. Capital for nearly US$250 million, as per the latest pharma acquisition news. The transaction amount to be paid by H.I.G. Capital, which is […]

Continue reading …
Sumitomo Dainippon Pharma to buy into Roivant Sciences Vants for $3bn

Sumitomo Dainippon Pharma has signed a deal worth $3 billion to assume ownership of stakes held by Roivant Sciences in certain biopharma companies (Vants), as per the latest pharma acquisition news. The deal will help in creating a biopharma alliance between the two companies. As per the terms of the deal, the Japanese pharma company […]

Continue reading …
Vertex to acquire Semma Therapeutics to advance stem cell-based treatments for type 1 diabetes

Vertex acquisition of Semma Therapeutics : US biotechnology company Vertex Pharmaceuticals has agreed to acquire privately-held biotechnology company Semma Therapeutics for $950 million in cash, as per the latest pharma acquisition news. Both the pharma companies are based in Massachusetts. Post-acquisition, Vertex Pharmaceuticals will advance curative cell-based treatments of Semma Therapeutics for type 1 diabetes and […]

Continue reading …
Page 1 of 3123